Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
NCT07094048Phase 4Recruiting
- Sponsor
- CHU de Québec-Université Laval
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 4 trial of polyvalent human immunoglobulin in Infection, sponsored by CHU de Québec-Université Laval. Started Jan 2026; status: recruiting.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
Infection
Beyond the preview
Go deeper on NCT07094048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07094048.